METiS Therapeutics and Huahai Pharmaceutical Announce Strategic Collaboration to Co-Develop AI-Driven Formulation Pipeline

VCBeat has learned that on December 4, 2020, Huahai Pharmaceutical, a well-known listed pharmaceutical company in China, entered into a strategic partnership with METiS TechBio, an AI-driven formulation development company. Huahai Pharmaceutical will select METiS TechBio as its preferred computational formulation service provider. The two parties will pool resources to jointly develop pipelines and build an AI-powered advanced formulation and drug delivery platform. Furthermore, leveraging their respective resources, they will establish and share an expert database, as well as co-develop and co-build a process engineering equipment platform, aiming to accelerate the R&D cycle of new drug clinical pipelines and thereby develop drugs with high economic value.

Huahai Pharmaceutical is a leading enterprise in domestic new drug R&D, with core products including ACE inhibitors and ARBs for hypertension. The company is also the first in China to obtain finished dosage form certification from the U.S. FDA, and it holds a leading position among domestic peers in international GMP certification, overseas registration of finished dosage forms and active pharmaceutical ingredients (APIs), and international cooperation.

METiS TechBio was incubated by XtalPi, a renowned company specializing in drug polymorph research and development. Inheriting XtalPi’s robust computational capabilities, METiS has chosen to focus on the field of formulation development, becoming the world’s first startup to drive pharmaceutical formulation development through computation. Committed to leveraging technologies such as high-throughput formulation platforms and intelligent computing, METiS provides pharmaceutical companies with rapid, precise, and intelligent formulation R&D services. Additionally, the company is developing novel formulated drugs in areas such as cancer and infectious diseases, delivering high-quality and highly effective medications to patients.